Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PASKALIUM vs P.A.S. SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
P. A. S. (p-aminosalicylic acid) sodium is a bacteriostatic agent that competitively inhibits the synthesis of folic acid in Mycobacterium tuberculosis by antagonizing the incorporation of p-aminobenzoic acid (PABA) into dihydrofolate. It is selective for mycobacterial folate synthase.
Treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with other antituberculosis agents
Treatment of tuberculosis (TB) in combination with other antituberculosis agents, particularly in multidrug-resistant TB (FDA-approved).,Off-label: Used as a second-line agent in atypical mycobacterial infections and in Crohn's disease (though not FDA-approved for these indications).
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
Oral: 4 g three times daily (total daily dose 12 g); IV: 12 g daily in 2-4 divided doses.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min).
1 hour (normal renal function); prolonged to 5-7 hours in anuria or severe renal impairment; clinical context: requires frequent dosing or renal dose adjustment
PASKALIUM is hydrolyzed in the gastrointestinal tract to PAS; PAS is primarily metabolized via acetylation (N-acetyltransferase) and conjugation with glycine.
Primarily metabolized by hepatic acetylation via N-acetyltransferase (NAT); minor pathways include glycine conjugation and renal excretion of unchanged drug.
Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%).
Renal (80% as active drug and metabolites, primarily acetylated form); fecal (minor; <10%)
98% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin.
50-60% (primarily to albumin)
Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution, likely due to high lipophilicity.
0.5-0.6 L/kg (indicates distribution into total body water, with some tissue binding)
Oral: 85-90% (first-pass metabolism minimal); intramuscular: 95%; intravenous: 100%.
Oral: approximately 90% (well absorbed from GI tract)
GFR >60: no adjustment; GFR 30-60: 250 mg daily; GFR <30: 125 mg daily.
Cr Cl <50 m L/min: reduce dose by 50%; Cr Cl <10 m L/min: avoid use or reduce to 25% of normal dose.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: 125 mg daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
10 mg/kg/day orally in divided doses every 12 hours.
Oral: 200-300 mg/kg/day in 3-4 divided doses, maximum 12 g/day.
Start at 250 mg daily; adjust based on renal function.
Start at lower end of dosing range; monitor renal function and adjust based on Cr Cl; typical initial dose 4 g twice daily.
None.
None explicitly stated in current FDA labeling; however, caution is advised in hepatic impairment due to risk of hepatitis.
May cause gastrointestinal irritation, hepatotoxicity, and hypersensitivity reactions. Monitor liver function and renal function during therapy.
May cause severe hypersensitivity reactions (e.g., fever, rash, lymphadenopathy).,Hepatic toxicity: risk of hepatitis, especially with prolonged use; monitor liver function.,Renal impairment: dose adjustment required in severe renal disease.,Gastrointestinal intolerance: nausea, vomiting, diarrhea common.,Development of resistance if used as monotherapy.,May induce hemolytic anemia in G6PD deficiency.
Hypersensitivity to para-aminosalicylic acid or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min)
Hypersensitivity to p-aminosalicylic acid or any component.,Severe hepatic impairment.,Severe renal failure (unless dose-adjusted).,Contraindicated in patients with active peptic ulcer disease.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes). Use of potassium-containing salt substitutes is contraindicated.
Take with food, especially acidic foods (e.g., applesauce, yogurt) to improve taste and reduce gastrointestinal irritation. Avoid alkaline foods (e.g., milk, antacids) as they may decrease absorption. Avoid alcohol due to increased risk of hepatotoxicity.
PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcomes. First trimester: no known risk. Second trimester: no known risk. Third trimester: maternal electrolyte disturbances may affect fetal heart rate and uterine contractility.
First trimester: No evidence of teratogenicity in human studies; limited animal data show no adverse effects. Second trimester: No specific risks identified. Third trimester: No known adverse fetal effects; use only if clearly needed.
Potassium is a normal constituent of breast milk. PASKALIUM is compatible with breastfeeding. M/P ratio: not applicable as potassium is endogenous. No adverse effects on nursing infant reported.
Excreted into breast milk in low amounts; M/P ratio not determined. Considered compatible with breastfeeding; monitor infant for diarrhea or rash.
Pregnancy may alter potassium distribution due to increased plasma volume. Dosing should be individualized based on serum potassium levels. No fixed dose adjustment required; titrate to maintain normal potassium levels (3.5-5.0 m Eq/L).
No pharmacokinetic changes requiring dose adjustment in pregnancy; use standard dosing but monitor for hepatotoxicity, which may be increased.
PASKALIUM is a potassium-sparing diuretic used for hypertension and edema. Monitor serum potassium regularly; avoid in severe renal impairment or hyperkalemia. Coadministration with ACE inhibitors or NSAIDs increases hyperkalemia risk.
Sodium aminosalicylate (PAS sodium) is a second-line antituberculosis agent used in multidrug-resistant TB (MDR-TB). It is bacteriostatic against Mycobacterium tuberculosis by inhibiting folate synthesis. Must be administered with other antitubercular drugs to prevent resistance. Monitor for hepatotoxicity, hypersensitivity reactions (fever, rash, eosinophilia), and gastrointestinal intolerance. Can cause hypothyroidism; monitor thyroid function. Drug interactions: may increase phenytoin levels; avoid concurrent probenecid (increases PAS levels). PAS granules should be sprinkled on soft acidic food to reduce GI upset.
Take exactly as prescribed; do not skip doses or double up.,Avoid potassium-rich foods and salt substitutes unless directed.,Report muscle weakness, irregular heartbeat, or signs of hyperkalemia.,May cause dizziness; avoid driving until effects known.
Take this medication exactly as prescribed, usually twice daily with food to reduce stomach upset.,Do not skip doses; complete the full course to prevent drug resistance.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe abdominal pain.,Notify your doctor if you develop fever, rash, or unusual tiredness.,You may need regular blood tests to monitor thyroid and liver function.,Avoid alcohol while taking this medication.,Keep all appointments for TB treatment monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PASKALIUM vs P.A.S. SODIUM, answered by our medical review team.
PASKALIUM is a Antitubercular Agent that works by PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.. P.A.S. SODIUM is a Antitubercular Agent that works by P. A. S. (p-aminosalicylic acid) sodium is a bacteriostatic agent that competitively inhibits the synthesis of folic acid in Mycobacterium tuberculosis by antagonizing the incorporation of p-aminobenzoic acid (PABA) into dihydrofolate. It is selective for mycobacterial folate synthase.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PASKALIUM and P.A.S. SODIUM depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PASKALIUM is: PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.. The standard adult dose of P.A.S. SODIUM is: Oral: 4 g three times daily (total daily dose 12 g); IV: 12 g daily in 2-4 divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PASKALIUM and P.A.S. SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PASKALIUM is classified as Category C. PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcom. P.A.S. SODIUM is classified as Category C. First trimester: No evidence of teratogenicity in human studies; limited animal data show no adverse effects. Second trimester: No specific risks identified. Third trimester: No kn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.